Gerard van Rhoon

Dr. Gerard van Rhoon

Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2000 in The Lancet
Verified
Journal Article
Closed access
JZJacoba van der Zee
Jacoba van der Zee
DGDionisio González
Dionisio González
Gerard van RhoonGerard van Rhoon
Gerard van Rhoon
JDJan Dp van Dijk
Jan Dp van Dijk
WPWim Lj van Putten
Wim Lj van Putten
AHAugustinus Am Hart
Augustinus Am Hart

1 July 1996 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
INInternationalcollaborativehypert
Internationalcollaborativehypert
CVC Vernon
C Vernon
JHJ Hand
J Hand
SFS Field
S Field
DMD Machin
D Machin
JVJ Vandijk
J Vandijk

4 April 2013 in European Radiology
Verified
Journal Article
Closed access
PDF file
Gerard van RhoonGerard van Rhoon
Gerard van Rhoon
Theodoros SamarasTheodoros Samaras
Theodoros Samaras
PYPavel S. Yarmolenko
Pavel S. Yarmolenko
MDMark W. Dewhirst
Mark W. Dewhirst
ENEsra Neufeld
Esra Neufeld
NKNiels Kuster
Niels Kuster

1 January 2020 in Advanced Drug Delivery Reviews
Verified
Journal Article
Open access
ASA.L.B. Seynhaeve
A.L.B. Seynhaeve
MAM. Amin
M. Amin
DHD. Haemmerich
D. Haemmerich
Gerard van RhoonGerard van Rhoon
Gerard van Rhoon
THTimo L. M. Ten Hagen
Timo L. M. Ten Hagen
Chemotherapy is a cornerstone of cancer therapy. Irrespective of the administered drug, it is crucial that adequate drug amounts reach all cancer cells. To achieve this, drugs first need to be absorbed, then enter the blood circulation, diffuse into the tumor interstitial space and finally reach the tumor cells. Next to chemoresistance, one of the most important factors for effective chemotherapy is adequate tumor drug uptake and penetration. Unfortunately, most chemotherapeutic agents do not have favorable properties. These compounds are cleared rapidly, distribute throughout all tissues in the body, with only low tumor drug uptake that is heterogeneously distributed within the tumor. Moreover, the typical microenvironment of solid cancers provides additional hurdles for drug delivery, such as heterogeneous vascular density and perfusion, high interstitial fluid pressure, and abundant stroma. The hope was that nanotechnology will solve most, if not all, of these drug delivery barriers. However, in spite of advances and decades of nanoparticle development, results are unsatisfactory. One promising recent development are nanoparticles which can be steered, and release content triggered by internal or external signals. Here we discuss these so-called smart drug delivery systems in cancer therapy with emphasis on mild hyperthermia as a trigger signal for drug delivery.

1 April 2010 in Journal of Controlled Release
Verified
Journal Article
Closed access
LLLi Li
Li Li
THTimo L.M. Ten Hagen
Timo L.M. Ten Hagen
DSDebby Schipper
Debby Schipper
TWTom M. Wijnberg
Tom M. Wijnberg
Gerard van RhoonGerard van Rhoon
Gerard van Rhoon
GKGerben A. Koning
Gerben A. Koning

1 June 2013 in Journal of Controlled Release
Verified
Journal Article
Closed access
LLLi Li
Li Li
THTimo L.M. Ten Hagen
Timo L.M. Ten Hagen
MHMartin Hossann
Martin Hossann
RSRegine Süss
Regine Süss
Gerard van RhoonGerard van Rhoon
Gerard van Rhoon
GKGerben A. Koning
Gerben A. Koning